Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III SYN2 PET Myocardial Perfusion Imaging in Suspected Coronary Artery Disease
2023-506971-89-00Phase 3Authorised
- Sponsor
- Syn2Bio
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of SYN1 in coronary arteriosclerosis, sponsored by Syn2Bio. Primary endpoint: Sensitivity and specificity of qualitative expert assessment of SYN2 PET MPI. Planned start Nov 2023; status: authorised.
02
Drugs
SYN1
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2023-506971-89-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506971-89-00.